← Back to Search

BETA-Text text messaging intervention for Breast Cancer

N/A
Waitlist Available
Led By Sarah Mougalian, MD
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial is comparing rates of continuation of any endocrine therapy between patients who only have standard of care follow-up and those who also have a bi-directional text messaging intervention. The secondary objectives are to assess time to permanent discontinuation of endocrine therapy, quality of life, adherence self-efficacy, financial burden, beliefs about medications, and perceived ability to communicate with one's physician.

Eligible Conditions
  • Breast Cancer
  • Medication Adherence
  • Side Effects

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Persistence to endocrine therapy at one year
Secondary outcome measures
Adherence self-efficacy
Beliefs about medication
Communication with one's physician
+8 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: BETA-Text InterventionExperimental Treatment1 Intervention
Patients in the text messaging arm will receive daily, weekly, and monthly text messages.
Group II: Usual CareActive Control1 Intervention
Patients in the usual care arm will not receive any text messages.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BETA-Text text messaging intervention
2019
N/A
~400

Find a Location

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,847 Previous Clinical Trials
2,736,128 Total Patients Enrolled
26 Trials studying Breast Cancer
2,835 Patients Enrolled for Breast Cancer
Sarah Mougalian, MDPrincipal InvestigatorYale University
1 Previous Clinical Trials
100 Total Patients Enrolled
1 Trials studying Breast Cancer
100 Patients Enrolled for Breast Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there still a chance to join this investigation?

"The clinicaltrials.gov database displays that this study is not currently recruiting patients, as the latest update was made on August 10th 2022 - since its initial posting in July 2019. Nonetheless, there are still over two thousand six hundred eighty-three trials actively looking for participants at present."

Answered by AI
Recent research and studies
JCO Clinical Cancer InformaticsJournal
Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-reported Outcomes in Breast Cancer
Mougalian, Sarah S., Lianne N. Epstein, Ami P. Jhaveri, Gang Han, Maysa Abu-Khalaf, Erin W. Hofstatter, Michael P. DiGiovanna, et al.. 2017. “Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-reported Outcomes in Breast Cancer”. JCO Clinical Cancer Informatics. American Society of Clinical Oncology (ASCO). doi:10.1200/cci.17.00015.
clinicaltrials.govStudy
Text Messaging in Patients on Adjuvant Endocrine Therapy for Breast Cancer
2019. "Text Messaging in Patients on Adjuvant Endocrine Therapy for Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03949270.
~70 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top